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Introduction: Extracellular adenosine triphosphate (ATP) stimulates vasodilation by binding to endothelial
ATP-selective P2Y2 receptors; a phenomenon, which is posited to be accelerated during exercise. Herein, we used
a rat model to examine how different dosages of acute oral ATP administration affected the femoral blood flow
response prior to, during, and after an exercise bout. In addition, we performed a single dose chronic administration
pilot study in resistance trained athletes.
Methods: Animal study: Male Wistar rats were gavage-fed the body surface area, species adjusted human
equivalent dose (HED) of either 100 mg (n=4), 400 mg (n=4), 1,000 mg (n=5) or 1,600 mg (n=5) of oral ATP as a
disodium salt (Peak ATP®, TSI, Missoula, MT). Rats that were not gavage-fed were used as controls (CTL, n=5). Blood
flow was monitored continuously: a) 60 min prior to, b) during and c) 90 min following an electrically-evoked
leg-kicking exercise. Human Study: In a pilot study, 12 college-aged resistance-trained subjects were given 400 mg
of ATP (Peak ATP®, TSI, Missoula, MT) daily for 12 weeks, and prior to an acute arm exercise bout at weeks 1, 4, 8,
and 12. Ultrasonography-determined volumetric blood flow and vessel dilation in the brachial artery was measured
at rest, at rest 30 minutes after supplementation, and then at 0, 3, and 6 minutes after the exercise.
Results: Animal Study: Rats fed 1,000 mg HED demonstrated significantly greater recovery blood flow (p < 0.01) and
total blood flow AUC values (p < 0.05) compared to CTL rats. Specifically, blood flow was elevated in rats fed 1,000 mg
HED versus CTL rats at 20 to 90 min post exercise when examining 10-min blood flow intervals (p < 0.05). When
examining within-group differences relative to baseline values, rats fed the 1,000 mg and 1,600 mg HED exhibited the
most robust increases in blood flow during exercise and into the recovery period. Human study: At weeks 1, 8, and 12,
ATP supplementation significantly increased blood flow, along with significant elevations in brachial dilation.
Conclusions: Oral ATP administration can increase post-exercise blood flow, and may be particularly effective
during exercise recovery.Background
Adenosine-5′-triphosphate (ATP) is involved in all
aspects of biosynthesis in cells and acts as the primary
intracellular energy source. Extracellular ATP and its
metabolites are involved in regulating a variety of bio-
logical processes including cardiac function, neurotrans-
mission, liver glycogen metabolism, muscle contraction
and blood flow [1].* Correspondence: jwilson06x@gmail.com
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unless otherwise stated.Oral ATP administration has been shown to improve
muscular function. Most episodes of lower back pain
arise from structures in the lumbar spine, including the
paravertebral musculature. ATP is linked to accelerating
recovery in people with lower back pain by improving
muscular cell function and increased blood flow [2].
Oral ATP administration has been shown to have an
early acting effect in sub-acute low back pain and has
been approved in France as an adjunct in the treatment
of lower back pain [2].
Supplementation of 225 mg per day of enteric-coated
ATP supplementation for 15 days resulted in increasedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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repetitions to failure on set one of three with 70% of
1RM [3]. Moreover, 15 days of 400 mg per day of ATP
supplementation reduced muscle fatigue and enabled a
higher force output during repeated high-intensity bouts
of exercise [4]. More recently, 12 weeks of 400 mg of
oral ATP disodium salt supplementation in resistance-
trained athletes utilizing a periodized resistance-training
program (RT) resulted in significant increases in lean
body mass, muscle thickness, total strength and vertical
jump power [5]. ATP also reduced protein breakdown
and limited the loss of strength and power during an
overreaching cycle [5].
Three distinct mechanisms-of-action have been pro-
posed for orally administered ATP’s ergogenic benefits:
1) ATP can increase blood flow, resulting in improved
oxygen and nutrient delivery to the muscle [5] 2) ATP
may increase muscular excitability [6]; 3) ATP can trigger
signaling cascades for metabolic adaptation related to
neuromuscular activity (phosphorylation of ERK1/2) (see
Figure 1) [7]. However, it is unlikely that oral ATP admi-
nistration will directly increase intramuscular ATP stores.
Erythrocytes function as an oxygen sensor, contribut-
ing to the regulation of skeletal muscle blood flow and
oxygen delivery, by releasing ATP in proportion to the
number of unoccupied oxygen binding sites in the he-
moglobin molecule. ATP release results in vasodilationFigure 1 Proposed mechanism-of-action of oral ATP administration.and greater blood flow to the working musculature,
thereby enhancing nutrient and oxygen delivery. Thus,
during exercise under hypoxic conditions, ATP is re-
leased from the red blood cells via pannexin channels.
ATP then binds to the purinergic receptors on the
endothelial cells [5]. The endothelial cells then produce
endothelium-derived hyperpolarizing factor, prostacyclin,
and nitric oxide, all of which serve to relax the smooth
muscle of the vasculature (see Figure 1) [5]. Infused ATP
has been shown to increase blood flow by stimulating
endothelial ATP-selective P2Y2 receptors and increasing
muscle sympathetic vasoconstrictor activity [8]. The va-
sodilatory and sympatholytic effects of exogenous ATP
are mediated via ATP itself rather than its dephospho-
rylated metabolites [9]. Chronic oral administration of
ATP in rats increased portal vein ATP concentration
and nucleoside uptake by erythrocytes, which resulted
in an increase in ATP synthesis in the erythrocytes [10].
To our knowledge, however, no studies have delineated
if oral ATP administration enhances the blood flow re-
sponse to exercise.
This study used a rat model to examine how different
dosages of acute oral ATP administration affected the
femoral blood flow response prior to, during, and after
an exercise bout. In addition, we performed a single dose
chronic administration pilot study in resistance trained
athletes.
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Animals and experimental protocol
All animal work was conducted in the Department of
Biomedical Sciences at the University of Missouri and
was approved by the University of Missouri’s Animal
Care and Use Committee. Male Wistar rats were ob-
tained from Charles River Laboratory weighing ~250 g.
Rats were allowed 7 days to acclimatize to new housing
and were maintained on a 12/12-h light/dark cycle, with
food (Harlan Laboratories, Tekland Global 14% Rodent
Maintenance diet) provided ad libitum until the experi-
mental testing day. On the morning of testing, rats had
food removed from homes cages at the beginning of the
light cycle. Eight hours later, each rat was placed under
isoflurane anesthesia and gavage-fed one of the following
in 2 ml of water: 3 mg ATP (human equivalent dose of
100 mg), n = 4; 12 mg ATP (human equivalent dose
of 400 mg), n = 4; 31 mg ATP (human equivalent dose of
1,000 mg), n = 5; 49 mg ATP (human equivalent dose of
1,600 mg), n = 5 or water only, n = 5 (CTL). All human
equivalent doses administered were based upon body sur-
face area conversion factors provided by Reagan-Shaw
et al. [11].
Following feeding, a blood flow probe (Transonic
Systems, Ithica, NY) was subsequently placed on the
proximal portion of the right femoral artery and stimula-
tion electrodes were placed in the right gastrocnemius
muscle for an electrically-evoked plantarflexion exercise
bout. Blood flow was then monitored continuously: a)
60 min prior to an electrically-evoked leg-kicking exercise
(60 V, 100 pps, for 3 min for a total of 180 contractions),
b) during the leg kicking exercise, and c) 90 min following
exercise. This exercise bout was chosen per previous lit-
erature demonstrating that this protocol elicited an in-
crease in femoral blood flow velocity in rats [12].
Subjects and experimental protocol
All human work was conducted in Department of Health
Sciences and Human Performance at the University of
Tampa and the protocol was approved by The University
of Tampa Institutional Review Board. In a pilot study, 12
resistance-trained male participants (age 23.7 ± 3.6 years;
height 179.0 ± 1.0 cm; weight 87.3 ± 6.1 kg) were given
400 mg of ATP as a disodium salt (Peak ATP®, TSI,
Missoula, MT) daily 30 minutes before breakfast for
12 weeks. In addition at the beginning of the study
and at weeks 1, 4, 8, and 12 subjects consumed the
400 mg of ATP 30 minutes prior to an acute elbow
flexor bout (3 sets of 20 contractions at 50% of the
subject’s 1-RM). Measurements were taken at weeks
0, 1, 4, 8, and 12. Ultrasonography-determined volu-
metric blood flow and vessel dilation in the brachial
artery [13] was measured at rest before taking the supple-
ment, at rest 30 minutes after supplementation, and thenat 0, 3, and 6 minutes after the exercise . An ultrasound
Doppler (LOGIQ e 2008, GE Healthcare, Wauwatosa, WI,
USA) equipped with an annular phased array transducer
probe (12-mm diameter), operating at an imaging fre-
quency of 7.5 MHz and variable Doppler frequencies of
4.0–6.0 MHz, was utilized to measure two-dimensional
(2D) brachial arterial diameter and mean blood velocity at
rest and following a one arm elbow flexor exercise bout.
The depth range of the ultrasound beam was greater than
the anatomic location of the brachial artery. Blood flow
(Q = vmean · A · 6 × 104, where vmean is mean blood vel-
ocity; l/min) was calculated from the amplitude (A) (signal
intensity)-weighted, time- and spatial- averaged vmean
(m/s), corrected for its angle of insonation, and multiplied
by A (m2) of the brachial artery. The intraclass correlation
coefficient (ICC) for the test–retest of blood flow and bra-
chial arterial diameter ranged from 0.91 to 0.93. The sub-
jects were fully informed of any risks and discomforts
associated with the experiments before giving their in-
formed written consent to participate. All subjects worked
with a registered dietician and were placed on a diet
consisting of 25% fat, 25% protein, and 50% carbohy-
drates. Inclusion/exclusion criteria indicated that sub-
jects had to have a minimum of 3 years of resistance
training experience and could not be taking any nu-
tritional supplements throughout the study. All subjects
were told to maintain their normal training volume
throughout the study.
Statistics
For the rat study, a two-way (treatment x time) mixed
factorial ANOVA with LSD post hoc analysis was per-
formed to determine if blood flow differed between treat-
ments at each 10-min post-gavage interval. If a significant
group, time, or group x time interaction existed the fol-
lowing statistical analyses were performed to further de-
compose the data: 1) individual independent samples
t-tests were performed between treatments at each time
point and significance was set at p < 0.01 in order to cor-
rect for an inflated type I error rate; 2) dependent t-tests
were performed within treatments whereby each time
point was compared to the baseline (-60 to -50 min) fe-
moral artery blood flow values. For the rat study, mean
femoral artery blood flow areas under the pre-exercise, ex-
ercise, post-exercise, and total blood flow curves (AUC)
were also computed using SigmaPlot 12.0 which uses the
trapezoidal rule algorithm for AUC calculations. Respect-
ive AUC values were compared between treatments using
one-way ANOVAs with LSD post-hoc analyses where ap-
propriate. All data were expressed as means ± standard
error values and significance was set at p < 0.05. For the
human data we used a repeated measures analysis of vari-
ance using Statistica (StatSoft®, Tulsa, OK, USA) to deter-
mine week, time, and week X time effects with an alpha
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was run in the event of a significant F-test.
Results
Animal data
There were significant group (p < 0.001) and time
(p < 0.001) effects, though no interaction effect (p > 0.05).
When examining within-group differences relative to
baseline values, ATP supplementation, independently
from the dose, did not increase blood flow pre-exercise.
Exercise significantly increased blood flow in all groups at
all time points during exercise compared to baseline
values within each treatment (p < 0.05). 3 mg ATP had no
effect on blood flow during the recovery period. 12 mg
ATP (p < 0.001), 31 mg ATP (p = 0.003), and 49 mg ATP
(p < 0.001) significantly increased blood flow 0 to 10 mi-
nutes post-exercise compared to baseline values within
each treatment. In addition, 49 mg ATP significantly
increased blood flow 10 to 20, and 20 to 30 minutes
post-exercise (p < 0.05) compared to baseline values.
Between-group comparisons at each time interval re-
vealed that mean arterial blood flow was elevated in
rats fed 31 mg versus Ex/CTL rats at 30 to 90 min
post exercise when examining 10-min blood flow in-
tervals (p < 0.01 to <0.001; Figure 2).
Rats fed 31 mg demonstrated significantly greater re-
covery blood flow (p = 0.007) and total blood flow AUC
values (p = 0.048) compared to CTL rats (Figure 3).Figure 2 Mean femoral artery blood flow (FABF) values for 10 min int
e-stim. exercise bout, and 0 to 90 min following exercise. Exercise incr
Independent t-tests with correction for multiple comparisons revealed that
Ex/CTL rats 30 to 90 min post-exercise (p < 0.01 to p < 0.001). All data areHuman data
At week 1 there was significant increase in blood flow at
0 min post exercise (Figure 4; p < 0.01) and tended to be
increased at 3 min post exercise (p = 0.07) in the ATP
supplemented relative to the control week (week 0). This
increase in brachial blood flow at week 1 was in con-
junction with a significant elevation in brachial dilation
at 0 min post exercise (Figure 5; p < 0.01). After 8 weeks
of ATP supplementation blood flow tended to be in-
creased at 0 min post exercise (p = 0.07) and was signifi-
cantly increased at 3 min post exercise at 8 weeks and
again at 12 weeks (p < 0.01 and p < 0.05, respectively)
relative to the control week. This again was in concur-
rence with a significant increase in brachial dilation
30 min after ATP treatment at rest at week 8 (p < 0.05)
and 6 min post exercise at 12 weeks (p < 0.01) and
tended to be increased 0 post exercise at 8 and 12 weeks
(p < 0.10) relative to the control week.
Discussion
Wilson et al. recently suggested that oral ATP supple-
mentation can significantly impact athletic performance,
skeletal muscle hypertrophy and recovery; however, the
study did not utilize methodologies to investigate the
potential mechanism for the observed ergogenic effects
[6]. One of the proposed mechanisms of action of oral
ATP administration is an increase in blood flow, resul-
ting in improved oxygen and nutrient delivery to theervals 60 to 0 minutes prior to exercise, during the 3-minute
eased blood flow within all groups compared to baseline values.
31 mg of oral ATP prolonged femoral artery blood flow compared to
presented as means ± standard errors; n = 4-5 animals per group.
Figure 3 Mean femoral artery blood flow (FABF) area under the curve (AUC) values prior to exercise (A), during the 3-minute e-stim.
exercise bout (B) , during the 90 min recovery period following exercise (C), and during the entire monitoring period (D). During the
recovery period, 31 mg of ATP increased blood flow compared to Ex/CTL, 3 mg, and 49 mg (p < 0.05). During the recovery period, 31 mg of ATP
increased blood flow compared to Ex/CTL, 3 mg of ATP, and 49 mg of ATP. During the total monitoring period, 31 mg of ATP increased blood
flow compared to Ex/CTL, and 49 mg of ATP. All data are presented as means ± standard errors; n = 4-5 animals per group.
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muscle is expected to improve removal of metabolic
waste products such as lactate and urea. Following exer-
cise nutrient delivery and cell swelling play a vital role in
the skeletal muscle adaptation response. Improvements
in blood flow conceivably would allow for greater deliv-
ery of nutrients for skeletal muscle repair following a
muscle damaging bout of training resulting in increases
in muscle hypertrophy previously seen with oral ATP
administration. The main finding of this study was thatFigure 4 Changes in brachial blood blow at weeks 1, 4, 8, 12
were compared to control week by a paired t-test, ‡p < 0.01,
*p < 0.05 and +p < 0.10.orally administered ATP as a disodium salt indeed in-
creases blood flow in exercising animals and humans,
most prominently during the recovery period from exer-
cise. Significant improvements could be measured at a
daily dose of 400 mg ATP in as little as one week in the
human study.
Though the exact mechanism of oral ATP absorption
is currently not fully understood, animal studies have
shown that the chronic oral administration of ATP re-
sulted in measurable changes in muscle metabolism,Figure 5 Changes in Brachial Diameter at weeks 1, 4, 8, 12
were compared to control week by a paired t-test, ‡p < 0.01,
*p < 0.05 and +p < 0.10.
Jäger et al. Journal of the International Society of Sports Nutrition 2014, 11:28 Page 6 of 7
http://www.jissn.com/content/11/1/28peripheral blood flow, and blood oxygenation [10,14]
and human studies have resulted in significant improve-
ments in body composition and performance [4,6].
Studies on the oral availability of ATP showed that it is
unlikely that oral ATP administration will directly increase
intramuscular ATP stores as a single dose of orally admin-
istered ATP in humans did not increase ATP concentra-
tions in blood [15]. The measurement of circulating free
plasma ATP derived from oral ATP supplementation
is very unlikely because exogenous free ATP is rapidly
taken up by blood components or is rapidly metabolized.
Kichenin et al. showed, in rats, that chronic oral adminis-
tration of ATP increased portal vein ATP concentration
and nucleoside uptake by erythrocytes, which resulted
in an increase in ATP synthesis in the erythrocytes [10].
In other animal studies the administration of oral ATP
resulted in a rapid degradation through ectonucleotidase
triphosphatase diphosphohydrolase 1 (CD39), present
on the luminal side of intestinal enterocytes, which de-
phosphorylate ATP via ADP to AMP, after which ecto-5′-
nucleotidase (CD73) degrades AMP to adenosine [16,17].
Following absorption of adenosine and inorganic phos-
phate in the small intestine and the portal circulation
these moieties are then incorporated into liver ATP pools,
leading to expansions of these pools. Therefore, the sys-
temic and oral administrations of ATP result in the expan-
sions of liver, blood (red blood cells) and blood plasma
(extracellular) pools of ATP which were shown for the
first time by Rapaport et al. [18,19].
Blood flow during exercise is indicative of nutrient
(amino acids, glucose, etc.) and oxygen delivery rate. As
such, increased blood flow will indicate greater nutrient
availability for the working musculature, and, in theory,
the muscle should have the capacity to recover more
quickly between sets, maintain performance longer, and
repair microtrauma more efficiently between training
sessions. Wilson et al. [6] hypothesized that the observed
increases in lean body mass, markers of athletic per-
formance, and resistance to an overreaching status with
chronic ATP supplementation were due to enhanced
blood flow leading to enhanced recovery, although this
remained to be directly examined until the current study.
However, despite increased blood flow during ATP infu-
sion, oxygen consumption does not increase [20]. Consid-
ering these two studies, it is possible that ATP is more
efficacious for anaerobic versus aerobic based exercise.
However, ATP’s efficacy in an endurance model re-
mains to be investigated. Likewise, the exact mechan-
ism whereby ATP increases post-exercise blood flow
also remains to be determined, although others have
hypothesized that this may be due to: a) ATP degradation
products being taken up by erythrocytes and resyn-
thesized into ATP; b) vasodilation of ATP degradation
(i.e., adenosine) products; and/or c) adenosine-stimulatednitric oxide and prostacyclin synthesis and downstream
signaling [4].
L-citrulline or L-arginine are amino acid precursors to
nitric oxide and have been marketed as potential ergogenic
aids based on their ability to increase blood flow to the ex-
ercising muscle. However, the daily dose needed to increase
blood flow is high (6-24 g) and the ergogenic response may
depend on the training status and health of the subjects
[21]. Whereas some studies involving untrained or mode-
rately healthy subjects showed that nitric oxide donors
could improve tolerance to aerobic and anaerobic exercise,
no significant improvements were measured in healthy [22]
or highly-trained subjects [21,23]. In contrast, oral ATP in-
creases blood flow at mg doses and has been shown to in-
crease lean body mass, strength and power in highly
trained individuals [6]. Therefore, oral ATP supplementa-
tion is an apparently efficacious method if the intent is in-
creasing post-exercise blood flow and nutrient delivery.
Limitations of this study include the lack of control
group and a rigorous control of other potentially con-
founding variables such as potential differences in exercise
habits or baseline dietary habits and dietary supplement
use in the human data. We propose future research to as-
sess the effects of oral ATP administration on blood flow
in a placebo-controlled crossover or parallel design.
Conclusion
Oral ATP administration can increase blood flow, and
this effect is particularly prominent following exercise.
Increased blood flow due to ATP supplementation may
be the mechanism responsible for ergogenic effects fol-
lowing chronic ATP supplementation as previously re-
ported in the scientific literature. However, the exact
mechanism whereby ATP increases blood flow during
post-exercise recovery periods remains unknown and fu-
ture investigation in this area is warranted.
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